As president and CEO of Prime Therapeutics, Mostafa Kamal leads Prime and Magellan Rx as a unified pharmacy solutions enterprise alongside over 7,000 dedicated colleagues who are passionate about partnering with our clients to provide high-quality, affordable care to millions of members across the United States. Under Kamal’s leadership, Prime is committed to delivering best-in-class pharmacy solutions tailored to meet the needs of the commercial, Medicare, Medicaid, and exchange markets. As part of the company’s commitment to innovation, Prime is laser focused on delivering intelligently designed solutions that simplify healthcare and improve transparency and affordability.

Kamal joined Prime through the company’s successful merger with Magellan Rx Management, where he had served as CEO since 2015. Kamal was instrumental in shaping the agreement that united Prime and Magellan Rx in December 2022, creating a next-generation pharmacy solutions company. After the merger, he continued as CEO of Magellan Rx and joined the Prime Therapeutics executive leadership team, first as executive vice president and then as president.

Earlier in his career, Kamal served as senior vice president and general manager of Magellan Rx Management’s specialty pharmacy business and well as chief underwriting officer for the organization. Prior to his time at Magellan Rx, Kamal held various roles with Medco Health Solutions, Inc. (now Express Scripts) with responsibility for pricing, underwriting, strategy and Medicare Part D products and services.

Kamal received his Bachelor of Science degree in economics from Rutgers University in New Brunswick, New Jersey.